Clinical Research of West Florida, Inc.

Summary

Clinical Research of West Florida, Inc. is a medical facility located in Clearwater, Florida. This center is recognized for care of Systemic Lupus Erythematosus, Crohn's Disease, Rheumatoid Arthritis, Lupus, Chronic Obstructive Pulmonary Disease and other specialties. Clinical Research of West Florida, Inc. is involved with conducting 155 clinical trials across 104 conditions. There are 5 research doctors associated with this hospital, such as Robert Levin, MD, Leonard Dunn, Leonard Jay Dunn, and Robert William Levin.

Top PIs

Clinical Trials running at Clinical Research of West Florida, Inc.

Systemic Lupus Erythematosus

Rheumatoid Arthritis

Psoriatic Arthritis

Lupus

Chronic Obstructive Pulmonary Disease

Sjogren's Syndrome

Sjögren's Syndrome

Cardiovascular Disease

Sjogren's syndrome

Smoking

Ianalumab

for Lupus

The trial will evaluate efficacy, safety and tolerability of two regimens of ianalumab compared to placebo, given as monthly or quarterly subcutaneous (s.c.) injection on top of standard-of-care (SoC) treatment in participants with active systemic lupus erythematosus (SLE).

Recruiting

1 award

Phase 3

1 criteria

Cenerimod

for Systemic Lupus Erythematosus

This trial is testing cenerimod, a medication aimed at reducing symptoms of Systemic Lupus Erythematosus (SLE) in adults with moderate to severe symptoms. Researchers want to see if cenerimod can help when added to existing treatments. The medication works by calming the overactive immune system, which may reduce inflammation and other symptoms.

Recruiting

1 award

Phase 3

2 criteria

Upadacitinib

for Lupus

Systemic Lupus Erythematosus (SLE) is an immune-mediated disease associated with inflammation of multiple organ systems. This study will assess how safe and effective upadacitinib is in treating adult participants with moderately to severely active SLE. Adverse events and change in the disease activity will be assessed. Upadacitinib is an approved drug for rheumatoid arthritis, psoriatic arthritis, and axial spondylarthritis and is being developed for the treatment of SLE. This study is "double-blinded", which means that neither the trial participants nor the study doctors will know who will be given upadacitinib and who will be given placebo (does not contain treatment drug) . This study comprised of 4 sub studies. In Study 1 and Study 2, study doctors put the participants in 1 of the 2 groups, called treatment arms. Each group receives a different treatment. There is a 1 in 2 chance that participants will be assigned to placebo. Eligible participants from Study 1 and Study 2 will enter Study 3 at week 52 to receive specific doses of upadacitinib. Study 4 is a 104-week continued extension if participation is likely to provide a benefit to their SLE. Approximately 500 participants diagnosed with SLE will be enrolled in each of the Study 1 and Study 2 in approximately 320 sites across the world. Participants will receive oral tablets of upadacitinib or matching placebo once daily for 52 weeks in Study 1 and Study 2. Eligible participants from Study 1 and Study 2 will receive oral tablets of upadacitinib once daily for 52 weeks in Study 3. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, checking for side effects and completing questionnaires.

Recruiting

1 award

Phase 3

10 criteria